Parmax Pharma Ltd (NSE: PARMAX), ISIN INE240T01014 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
PARMAX last traded at ₹109.09 (+1.99%), with a 52-week range of ₹22.60 to ₹109.20 (as of 30 Jul 2026).
Shareholding as of Dec 2025: promoters 30.80%, FIIs 0.00%, DIIs 0.00%, mutual funds 0.00%.
EquiSense Score (ECS): 25/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.